Patient income and health innovation
Authors:
- 14 September 2020
- journal article
- research article
- Published by Wiley in Health Economics
- Vol. 29 (12) , 1795-1803
Abstract
This study analyzes the relationship between the number of clinical trials in a disease area, the health losses from that disease, and the average income of people suffering from it. Average patient income appears strongly predictive of the number of clinical trials, whether funded by industry or not. We are able to precisely estimate the relationship between income and the number of trials and to identify both (a) the specific diseases that appear to be underfunded relative to their harm to human health and (b) the amount of additional funding required to bring innovation investment up to the present average.Keywords
Funding Information
- Canadian Institutes of Health Research
- Seventh Framework Programme (339239)
This publication has 16 references indexed in Scilit:
- Use of data from registered clinical trials to identify gaps in health research and developmentBulletin of the World Health Organization, 2013
- Non-communicable diseases: 2015 to 2025The Lancet, 2013
- Investments in Pharmaceuticals Before and After TRIPSReview of Economics and Statistics, 2012
- Innovation and the Burden of Disease: Retrospective Observational Study of New and Emerging Health Technologies Reported by the EuroScan Network from 2000 to 2009Value in Health, 2012
- IMPORTATION AND INNOVATIONEconomics of Innovation and New Technology, 2007
- Developing Drugs For Developing CountriesHealth Affairs, 2006
- Global notes: the 10/90 gap disparities in global health researchJournal of Perinatology, 2005
- Clinical Trial Registration: A Statement from the International Committee of Medical Journal EditorsNew England Journal of Medicine, 2004
- Setting global health research prioritiesBMJ, 2003
- General Assembly on September, 21, 1996Strahlentherapie und Onkologie, 1997